Abemaciclib: First-Line CDK4/6 Inhibitor for Breast Cancer
Abemaciclib, the third CDK4/6 inhibitor, in combination with endocrine therapy shows significant benefit for the first-line treatment of HR+ HER2- advanced breast cancer. Medscape Medical News …read more